Bot Detector
Download FREE Sample Issue or Article
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Methylphenidate in the Treatment of Attention Deficit Disorders

Author(s):  Tenreiro Kim

Issue:  Jan/Feb 2001 - Compounding for Pediatric Patients
View All Articles in Issue

Page(s):  21-22

Methylphenidate in the Treatment of Attention Deficit Disorders Page 1
Methylphenidate in the Treatment of Attention Deficit Disorders Page 2

Download in electronic PDF format for $75

Abstract:  The author reports on a randomized, single-blind trial of the effectiveness of methylphenidate vs. that of placebo in the treatment of pediatric patients with attention deficit disorder or attention-deficit hyperactivity disorder. Patients typically took one capsule twice a day for 14 days from one prescription, then switched to the other prescription for 14 days, with the pharmacist randomly assigning when the patient took methylphenidate or placebo. Patient caregivers completed a consent form and an evaluation form. Of the 429 trials involving 409 patients carried out at the author’s pharmacy, about one third of patients returned evaluation forms. Results showed that 22.4% (47/210) of subjects studied did not receive methylphenidate after the trial and that 93% of respondents (132/142) thought that the trial was worthwhile. The author concludes that providing a trial program provides the following benefits: a significant number of patients become steady customers; referrals are generated from friends and neighbors of subjects’ parents, in addition to school personnel and pediatricians; and physicians have a tool to evaluate drug effectiveness in patients.

Related Keywords: ADD, attention deficit, attention deficit disorder, children, Methylphenidate, pediatric, placebo


Printer-Friendly Version

Related Articles from IJPC
(Click for Abstract / Details / Purchase)
Methylphenidate in the Treatment of Attention Deficit Disorders
Tenreiro Kim
Jan/Feb 2001
Pg. 21-22

Attention Deficit Hyperactivity Disorder
Allen Loyd V Jr
Mar/Apr 1997
Pg. 87-89

Methylphenidate 1-mg/mL Oral Liquid
Allen Loyd V Jr
May/Jun 2007
Pg. 249

Methylphenidate Hydrochloride 10-mg Capsules
Allen Loyd V Jr
Nov/Dec 2014
Pg. 501

Methylphenidate Hydrochloride 2.5-mg, 5-mg, or 10-mg Chewable Troches
Allen Loyd V Jr
May/Jun 2015
Pg. 244

Pediatric Compounding: Coloring Outside the Lines
Preckshot John
Jan/Feb 2001
Pg. 6-8

Sensitization Therapy for Warts
Kuntz Rachael
Jul/Aug 2003
Pg. 266-270

Skin Disorders in Horses; Case Report: Tripelennamine in the Treatment of Skin Disorders in Horses
Williams LaVonn A
, Fokken Dawn
Sep/Oct 2009
Pg. 386-389

Pediatric Dermatitis
Remmert Renee
Nov/Dec 2002
Pg. 419-421

Basics of Compounding for Disorders of the External Ear
Allen Loyd V Jr
Jan/Feb 2004
Pg. 46-48

Basics of Compounding for Raynaud's Disease
Glasnapp Andrew
Jul/Aug 2003
Pg. 288-291

Folinic Acid, L-DOPA, and 5-hydroxytryptophan in Tetrahydrobiopterin Deficiency: Treatment Plan for a Pediatric Patient
Bramwell Bethany
Jul/Aug 2011
Pg. 316-319

Azstarys in Ora-Blend Single Dose
Allen Loyd V Jr
May/Jun 2022
Pg. 233

Adderall 1-mg/mL Oral Liquid
Allen Loyd V Jr
Jul/Aug 2006
Pg. 299

Compounded Analgesic Therapy for Disorders of Movement: Arthritis, Neuropathic Pain, and Postpolio Syndrome
Brown Scott
, Erickson Brian, Muller George, Bryant-Snure Susan J, Mestayer Richard F III
May/Jun 2010
Pg. 182-192

Prednisolone Sodium Phosphate 1.4 mg/mL in SyrSpend SR pH4, Cherry Flavored
Allen Loyd V Jr
Nov/Dec 2019
Pg. 487

Prednisolone 1 mg/mL in SyrSpend SF pH4
Allen Loyd V Jr
May/Jun 2020
Pg. 229

Atomoxetine 4-mg/mL Oral Solution/Suspension
Allen Loyd V Jr
Jul/Aug 2021
Pg. 321

Dexmethylphenidate Hydrochloride 2.5-mg, 5-mg, or 10-mg Capsules
Allen Loyd V Jr
Nov/Dec 2014
Pg. 496

Treating Inner Ear Disorders with Intratympanic Drug Administration
McElhiney Linda F
Jul/Aug 2011
Pg. 302-307

Return to Top